Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Sarcoma"

23 News Found

Philogen completes patient enrollment of Phase III FIBROSARC trial in Soft Tissue Sarcoma
News | February 06, 2025

Philogen completes patient enrollment of Phase III FIBROSARC trial in Soft Tissue Sarcoma

These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential


Rare arm cancer defeated: Indore doctors save patient’s arm with complex surgery
News | January 01, 2026

Rare arm cancer defeated: Indore doctors save patient’s arm with complex surgery

The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement


Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
Clinical Trials | December 19, 2025

Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial

The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival


GSK’s experimental lung cancer drug gains FDA orphan drug status
Drug Approval | December 12, 2025

GSK’s experimental lung cancer drug gains FDA orphan drug status

GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization


Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
News | December 09, 2025

Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa

Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones


Philogen updates on Fibromun clinical study developments
Clinical Trials | November 13, 2025

Philogen updates on Fibromun clinical study developments

FIBROSARC did not meet its primary PFS endpoint in the final analysi


Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors
Clinical Trials | October 25, 2025

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile


Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Clinical Trials | October 23, 2025

Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients

Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile


SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
Healthcare | August 21, 2025

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction

The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries


Alembic announces USFDA final approval for single-dose vials
Drug Approval | June 29, 2025

Alembic announces USFDA final approval for single-dose vials

Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma